Ask AI
Back Back
Cholinergic Modulation in Schizophrenia
Cholinergic Connection: Beyond Dopamine Blockade in Schizophrenia Care

Released: December 18, 2025

Michael Asbach
Michael Asbach, DMSc, PA-C
Activity Information

Activity

Progress
1
Course Completed
Continue
Key Takeaways
  • Muscarinic agonism at M1/M4 represents a potential paradigm shift, offering antipsychotic efficacy without dopamine receptor blockade and fewer metabolic or motor side effects.
  • Schizophrenia is increasingly understood as a network-level disorder, and emerging treatments target upstream regulatory systems like the cholinergic pathway to restore functional circuit balance.
  • Integrating novel mechanisms, such as muscarinic M1/M4 agonism, into practice could personalize care, improving long-term outcomes by aligning treatment with both neurobiology and patient tolerability.

For more than 70 years, the treatment of schizophrenia has been defined by 1 fundamental principle: dopamine antagonism. From the serendipitous discovery of chlorpromazine in the early 1950s to the development of atypical agents, every approved antipsychotic until recently has shared a common thread of postsynaptic dopamine D2 receptor blockade. That discovery revolutionized psychiatry and transformed lives, but it also framed our understanding of psychosis around a single neurotransmitter system. Modern neuroscience now provides greater insight into the complexity of schizophrenia. The dopamine hypothesis, although historically useful, represents only 1 piece of a much larger neurobiologic puzzle.

The Dopaminergic Paradigm: Powerful but Imperfect
The dopamine hypothesis emerged from a convergence of pharmacologic observations: drugs that increased dopamine (such as amphetamines) could precipitate psychosis, whereas drugs that blocked dopamine reduced psychotic symptoms. This observational approach formed the original dopamine hypothesis, and for decades the field was built around the notion that “dopamine excess equals schizophrenia.” In clinical practice, D2 blockade is a blunt tool. It suppresses downstream signaling but fails to address the upstream dysregulation that drives excess dopamine signaling.

Traditional antipsychotics exert their effect by putatively blocking postsynaptic D2 receptors, which dampens dopaminergic transmission in the mesolimbic pathway and mitigates positive symptoms. However, this same blockade extends nonspecifically to other pathways such as the nigrostriatal (causing extrapyramidal symptoms), the tuberoinfundibular (causing hyperprolactinemia), and even the mesocortical (potentially worsening negative and cognitive symptoms). Complicating this further, antagonism at presynaptic D2 autoreceptors can paradoxically increase dopamine release, perpetuating a maladaptive feedback loop. The result is an approach that manages acute symptoms but does little to recalibrate the underlying circuitry.

This mechanistic imprecision has long been mirrored by our clinical observations. When clozapine was first synthesized, its lack of catalepsy was viewed not as an advantage but a flaw. Early investigators assumed that motor rigidity was a necessary indicator of antipsychotic potency. Ironically, the very side effect profile that made clozapine an outlier eventually became a defining strength. That historical anecdote underscores a broader truth: for much of our field’s history, we equated therapeutic success with the presence of tolerability trade-offs, simply because every effective drug we knew worked that way.

Beyond the Synapse: Toward Circuit-Level Modulation
Advances in neuroimaging, molecular biology, and computational modeling have reframed schizophrenia not as a monolithic dopamine disorder but as a network-level dysregulation of signal processing. Dysregulated presynaptic dopamine release, glutamatergic dysfunction, and impaired cortical-subcortical connectivity appear to converge to produce the clinical syndrome we call schizophrenia. If postsynaptic D2 antagonists are our “buckets” catching the leaks of dopaminergic overflow, then the next generation of therapeutics aims to patch the roof itself, targeting the upstream regulatory systems that govern dopaminergic tone.

Among these regulatory systems, the cholinergic network, particularly muscarinic M1 and M4 receptors, has re-emerged as a key player. Cholinergic signaling shapes cortical excitation, striatal dopamine release, and synaptic plasticity, processes fundamental to both psychosis and cognition. Modulating these receptors offers a potential way to rebalance dopaminergic and glutamatergic systems without directly blocking dopamine receptors. 

The Cholinergic Connection: M1/M4 Agonism Leads the Pack
Recent data with xanomeline/trospium provide compelling proof of concept for this “upstream” approach. Xanomeline, a selective M1/M4 muscarinic receptor agonist, was shown decades ago to reduce psychotic symptoms but its clinical implementation was limited by peripheral cholinergic side effects. By pairing xanomeline with trospium, a peripherally restricted muscarinic antagonist, investigators were able to counterbalance peripheral cholinergic effects while preserving central efficacy.

In the pivotal EMERGENT-2 and EMERGENT-3 trials, xanomeline/trospium demonstrated robust reductions in positive and negative syndrome scale total scores compared with placebo, with effect sizes on par with or exceeding many dopamine-blocking agents. Of importance, this benefit came without the hallmark liabilities of traditional antipsychotics: no extrapyramidal symptoms, no significant weight gain, and no prolactin elevation. The most common adverse effects were mild cholinergic symptoms such as nausea, constipation, and dyspepsia. Mechanistically, M1 activation enhances cortical glutamatergic signaling and supports cognitive processing, while M4 activation modulates presynaptic striatal dopamine release, dampening excessive dopaminergic drive where it’s most dysregulated. This dual mechanism marks an evolution in approach, focusing not on dopamine receptor antagonism but on upstream modulation of the circuits that govern dopaminergic signaling. Early data also suggest potential benefits for negative and cognitive symptoms, domains historically untouched by traditional dopamine antagonists.

From a healthcare professional’s perspective, this is more than a pharmacologic novelty; it is a philosophical pivot. We are moving from pharmacologic symptom control toward circuit-level modulation, from suppressing pathology to restoring functional balance. The goal is not to replace dopamine antagonists overnight but to expand our armamentarium with options that are both mechanistically rational and tolerable enough to sustain long-term engagement.

Other Novel Pathways: A Broader Frontier
Muscarinic agonism may be the current frontrunner, but it is not the only pathway being explored. Trace amine-associated receptor 1 (TAAR1) agonists, such as ulotaront, represent another nondopaminergic approach that indirectly modulates dopamine and serotonin signaling. Early-phase studies were promising, though recent phase III results have been mixed, underscoring the challenge of translating complex biology into consistent clinical outcomes. Similarly, NMDA receptor modulators, glycine transport inhibitors, and PDE10 inhibitors have attracted attention at various points over the past 2 decades, but have delivered variable efficacy or unacceptable safety profiles in later trials.

Yet even these disappointments serve a purpose. Each mechanistic foray helps refine our hypotheses, sharpen our biomarkers, and recalibrate the targets most likely to yield durable benefit. Progress in psychiatry has always been epistemic and iterative. Each experiment, successful or not, moves the field forward by narrowing the gap between hypothesis and human reality.

Clinical Implications: Toward Network-Informed Care
For practicing healthcare professionals, the arrival of new mechanistic classes invites both excitement and humility. Dopamine antagonists remain the backbone of acute psychosis management, and many patients will continue to do well on existing therapies. The integration of upstream modulators such as xanomeline/trospium and similar agents in development may enable more targeted treatment across symptom domains while reducing metabolic and motor side effects, ultimately improving adherence by better aligning efficacy and tolerability.

These advances also remind us that schizophrenia is not a single disease but a heterogeneous syndrome. A therapy that normalizes cortical cholinergic tone may profoundly benefit 1 subset of patients while offering modest gains for another. The path forward will likely involve combination and sequencing strategies, biomarker-guided selection, and openness to blending pharmacologic and psychosocial interventions aligned with the patient’s functional goals.

Conclusion: Incremental Innovation, Transformative Potential
When clozapine’s lack of rigidity was once mistaken for ineffectiveness, we learned that the absence of familiar side effects does not imply a lack of efficacy. We are now witnessing another potential paradigm shift: from postsynaptic dopamine blockade toward upstream, circuit-based modulation. Schizophrenia will not be solved by a single receptor or a single drug, but by a series of incremental innovations that collectively reduce disability and restore possibility.

For the first time in decades, we are not merely turning down the volume of dopamine; we are learning to tune the network itself. That, perhaps, is the true promise of the cholinergic connection.

Continue

Poll

1.

How do you anticipate this commentary will impact your clinical management of patients with schizophrenia?

Submit